Pfizer considers suing Metsera, Novo over topping bid
Digest more
The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.
Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward trends. Click for my NVO stock update.